GGrantIndex
← Leaderboards

Kathleen Ann Martin

Yale University

$14,895,788
Attributed
$16,973,729
Total exposure
10
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.7M · FY200825
$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$16,973,729 · 10

By mechanism

R01$16,933,729 · 8
R13$40,000 · 2

Top collaborators

Most similar at Yale University

Same institution · by research overlap

Others in their field

Top investigators on “Cardiovascular Diseases

Research focus

Cardiovascular DiseasesSmooth Muscle MyocytesPhenotypeAtherosclerosisGene ExpressionBlood VesselsResponseInjuryCell Differentiation ProcessIn VivoHyperplasiaGenesPathway InteractionsEpigenetic ProcessProteinsAngioplastyMyocardinIn VitroKnock-OutTransplantationGrowthPreventSirolimusRegulation

Grant awards (36)

Heterochromatin dynamics in vascular smooth muscle plasticity$756,224
R01 · FY2025 · HL · contact PI
Epigenetic-mediated Notch pathway activation promotes elastin aortopathy$654,729
R01 · FY2025 · HD
Epigenetic-mediated Notch pathway activation promotes elastin aortopathy$648,182
R01 · FY2024 · HD
Epigenetic-mediated Notch pathway activation promotes elastin aortopathy$654,729
R01 · FY2023 · HD
Role of LMO7 in atherosclerosis$534,519
R01 · FY2023 · HL · contact PI
Vascular Discovery, From Genes to Medicine 2023$20,000
R13 · FY2023 · HL · contact PI
Coordinated regulation of vascular smooth muscle phenotype by p300, CBP, and TET2$548,500
R01 · FY2022 · HL · contact PI
Role of LMO7 in atherosclerosis$534,519
R01 · FY2022 · HL · contact PI
2022 Vascular Discovery: From Genes to Medicine$20,000
R13 · FY2022 · HL · contact PI
Novel insights into intimal hyperplasia in cardiac allograft vasculopathy$603,930
R01 · FY2021 · HL · contact PI
Role of LMO7 in atherosclerosis$568,019
R01 · FY2021 · HL · contact PI
Coordinated regulation of vascular smooth muscle phenotype by p300, CBP, and TET2$548,500
R01 · FY2021 · HL · contact PI
Novel insights into intimal hyperplasia in cardiac allograft vasculopathy$603,930
R01 · FY2020 · HL · contact PI
Role of LMO7 in atherosclerosis$568,019
R01 · FY2020 · HL · contact PI
Coordinated regulation of vascular smooth muscle phenotype by p300, CBP, and TET2$548,500
R01 · FY2020 · HL · contact PI
Novel insights into intimal hyperplasia in cardiac allograft vasculopathy$603,930
R01 · FY2019 · HL · contact PI
Coordinated regulation of vascular smooth muscle phenotype by p300, CBP, and TET2$552,743
R01 · FY2019 · HL · contact PI
Novel insights into intimal hyperplasia in cardiac allograft vasculopathy$603,930
R01 · FY2018 · HL · contact PI
Novel Targets of Rapamycin & Akt in VSMC Differentiation$416,250
R01 · FY2017 · HL · contact PI
Epigenetic control of vascular smooth muscle in cardiovascular disease$416,250
R01 · FY2017 · HL · contact PI
Regulation of vascular smooth muscle cell plasticity$416,250
R01 · FY2017 · HL · contact PI
Regulation of vascular smooth muscle cell plasticity$416,250
R01 · FY2016 · HL · contact PI
Novel Targets of Rapamycin & Akt in VSMC Differentiation$416,250
R01 · FY2016 · HL · contact PI
Epigenetic control of vascular smooth muscle in cardiovascular disease$416,250
R01 · FY2016 · HL · contact PI
Novel Targets of Rapamycin & Akt in VSMC Differentiation$410,006
R01 · FY2015 · HL · contact PI
Epigenetic control of vascular smooth muscle in cardiovascular disease$410,006
R01 · FY2015 · HL · contact PI
Regulation of vascular smooth muscle cell plasticity$410,006
R01 · FY2015 · HL · contact PI
Regulation of vascular smooth muscle cell plasticity$416,250
R01 · FY2014 · HL · contact PI
Epigenetic control of vascular smooth muscle in cardiovascular disease$416,250
R01 · FY2014 · HL · contact PI
Novel Targets of Rapamycin & Akt in VSMC Differentiation$407,925
R01 · FY2014 · HL · contact PI
Novel Targets of Rapamycin & Akt in VSMC Differentiation$396,270
R01 · FY2013 · HL · contact PI
Novel targets of rapamycin and Akt in vascular smooth muscle cell differentiation$409,613
R01 · FY2012 · HL · contact PI
Novel targets of rapamycin and Akt in vascular smooth muscle cell differentiation$413,750
R01 · FY2011 · HL · contact PI
Novel targets of rapamycin and Akt in vascular smooth muscle cell differentiation$413,750
R01 · FY2010 · HL · contact PI
Novel targets of rapamycin and Akt in vascular smooth muscle cell differentiation$399,750
R01 · FY2009 · HL · contact PI
Novel targets of rapamycin and Akt in vascular smooth muscle cell differentiation$399,750
R01 · FY2008 · HL · contact PI